Cancer clinical trials in the region Occitanie

306 currently recruiting clinical trials

Looking for clinical trials?

Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:

Create your account
Copy-paste your latest medical report
Our AI-based assistant does the rest for you

Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:

Create your account
and find trials relevant to your profile

Phase 2 Ovarian / Fallopian tubes / Peritoneum cancer #NCT04602377 #2024-515310-40-01

Ajout de pembrolizumab à la chimiothérapie standard chez les patients atteints de cancer de l'ovaire à petites cellules de type hypercalcémique

Other ovarian cancer Localized Locally Advanced Metastatic None Systemic Treatment-Naive Systemic Treatment-Naive

Immunotherapy Chemotherapy Immunotherapy Chemotherapy

IUCT Oncopôle (Toulouse)

ARCAGY/ GINECO GROUP

Phase 2 Ovarian / Fallopian tubes / Peritoneum cancer #NCT05872204

Abémaciclib et létrozole chez les patientes atteintes d'un cancer de l'ovaire rare à récepteurs d'œstrogènes positifs

Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC) Other ovarian cancer Serous low grade carcinoma (LGSOC) Endometrioid carcinoma Stromal cells and sex cords tumor HR Positive Locally Advanced Metastatic 1 2 3 or more Chemotherapy Hormone therapy

Systemic Treatment-Naive

IUCT Oncopôle (Toulouse)

Universitaire Ziekenhuizen KU Leuven

Phase 2 Ovarian / Fallopian tubes / Peritoneum cancer #NCT05128825

[DENALI] Étude de l'azénosertib (ZN-c3) chez des patientes atteintes d'un cancer séreux de haut grade de l'ovaire, de la trompe de Fallope ou du péritoine primitif résistant au platine

Partie 2a Bras 1 et 2 et partie 2b (Cyclin E1 positive)

Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC) Serous high grade carcinoma (HGSOC) Other mutation 1 2 3 or more Recurrence within 6 months after platinum-based tr... Chemotherapy Chemotherapy

Systemic Treatment-Naive Systemic Treatment-Naive

IUCT Oncopôle (Toulouse)

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

Phase 2 Endometrial cancer #NCT06906341 #2024-517432-21-00

[BELLA] RELACORILANT en association avec différents schémas thérapeutiques chez les patientes atteintes de cancers gynécologiques

Bras C

Stage III Stage IV Locally Advanced Metastatic 1 2 Immunotherapy Chemotherapy

Systemic Treatment-Naive

Centre Hospitalier Universitaire de Toulouse (Toulouse)

Corcept Therapeutics

Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06760819 #2024-517419-62-00

[panSOHO] Etude sur l'efficacité du BAY2927088 et sur son innocuité chez les participants atteints d'une tumeur solide présentant des mutations activatices d'HER2

Stomach Oesogastric junction Esophagus Adenocarcinoma Intrahepatic cholangiocarcinoma Extrahepatic cholangiocarcinoma Ampullary carcinoma Gastrointestinal stromal tumor Squamous cell carcinoma Other HER2 Positive Locally Advanced Metastatic Metastatic Castration-resistant HER2 1

Systemic Treatment-Naive

Institut du cancer de Montpellier (Montpellier)

Bayer

Phase 2 Liver and bile duct cancer #NCT06904170 #2024-514912-28-00

[ALICE] Durvalumab et trémélimumab avec ou sans perfusion intra-artérielle hépatique de chimiothérapie dans le carcinome hépatocellulaire

Hepatocellular carcinoma Unhealthy A None Systemic Treatment-Naive Systemic Treatment-Naive

Transarterial chemoembolization

Centre Hospitalier Universitaire de Toulouse (Toulouse)

UNICANCER

Phase 2 Lymphoma #NCT05283720 #2023-505347-38-00

Etude de l'innocuité et la tolérabilité de l'EPCORITAMAB en association avec des agents antinéoplasiques chez les participants adultes atteints d'un lymphome non hodgkinien - Bras 1 à 4

B cell lymphoma Large B cell lymphoma Indolent transformed lymphoma None 1 2 3 or more

Bispecific T-cell engager antibodies

IUCT Oncopôle (Toulouse)

Abbvie

Phase 2 Breast cancer #NCT04965766 #2023-505923-30-00

[ICARUS-BREAST] Étude du PATRITUMAB DERUXTECAN (U3-1402) dans le cancer du sein localement avancé ou métastatique inopérable

HER2 Negative HR Positive Locally Advanced Metastatic Chemotherapy Targeted therapy Hormone therapy

Centre Hospitalier Universitaire de Toulouse (Toulouse), Institut du cancer de Montpellier (Montpellier)

Gustave Roussy, Campus du cancer, Grand Paris

Phase 2 Rectal cancer #NCT04749108 #2021-000414-41

[GRECCAR14] Étude évaluant la prise en charge personnalisée du cancer du rectum localement avancé

Adenocarcinoma Locally Advanced None Systemic Treatment-Naive

Centre Hospitalier Universitaire de Toulouse (Toulouse), Institut du cancer de Montpellier (Montpellier), Centre Hospitalier Universitaire de Nîmes (Nîmes)

Institut du Cancer de Montpellier - Val d'Aurelle

Phase 2 Ovarian / Fallopian tubes / Peritoneum cancer #NCT05183984 #2023-504166-37-00

[NIRVANA-1] NIRAPARIB avec BEVACIZUMAB BeVAcizumab après cytoréduction complète chez les patientes atteintes d'un cancer de l'ovaire

Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC) Serous high grade carcinoma (HGSOC) Endometrioid carcinoma Stage III Locally Advanced None Surgery

Targeted therapy Targeted therapy

IUCT Oncopôle (Toulouse)

Groupe ARCAGY/GINÉCO